Garetosmabdosage Garetosmab is a fully human monoclonal antibody developed to inhibit activin A, a protein implicated in fibrodysplasia ossificans progressiva (FOP). This investigational therapy, also known by its research code REGN 2477, represents a significant advancement in the potential treatment of this rare and debilitating genetic disorder characterized by abnormal bone formation. Garetosmab's mechanism of action centers on neutralizing activin A, thereby aiming to prevent the progression of heterotopic ossification (HO), which is the hallmark of FOPHere, we report the clinical pharmacology data from LUMINA-1 (NCT03188666), a Phase 2 trial that evaluatedgaretosmab(a monoclonal antibody against activin A) ....
Fibrodysplasia ossificans progressiva (FOP) is an extremely rare connective tissue disease that causes progressive and irreversible heterotopic ossification.By binding and blocking Activin A,garetosmabmay prevent the formation and stop the growth of HO in FOP.Garetosmabhas received Orphan Drug status for FOP ... This means that soft tissues, such as muscles, tendons, and ligaments, gradually turn into boneGaretosmab (REGN 2477) | CAS 2097125-54-5. These episodes of abnormal bone formation are often triggered by minor injuries and can lead to severe disability, pain, and reduced mobility.Garetosmab is an anti-activin A antibodythat was tied to a 90% or greater reduction in new abnormal bone lesions. The outcome supports Regeneron's findings ... The disease affects individuals worldwide, with estimates suggesting a prevalence of about one in a million.
Garetosmab, as an anti-activin A monoclonal antibody, targets a key mediator in the pathological process of FOPGaretosmab (REGN 2477) | Anti-Activin A mAb. Activin A is a member of the TGF-beta superfamily and plays a crucial role in various biological processes, including bone formation and tissue repair. In FOP, dysregulation of activin A signaling is believed to contribute to the excessive and misplaced bone growth. By binding to and neutralizing activin A, garetosmab aims to disrupt this signaling pathway and halt the formation of new abnormal bone.
The development of garetosmab has been a subject of intense research and clinical trials2025年9月17日—Garetosmab is a monoclonal antibody that neutralizes the Activin A protein, which Regeneron scientists discovered to be a critical protein .... Regeneron Pharmaceuticals, the developer of garetosmab, has been at the forefront of investigating its efficacy and safety. Clinical studies, such as the OPTIMA Phase 3 trial and earlier Phase 2 trials like LUMINA-1, have been instrumental in evaluating the drug's impact on preventing new bone lesions and managing FOP progressionGaretosmab|Cas# 2097125-54-5.
Early trial results have shown promising outcomes, with garetosmab demonstrating a significant reduction in new abnormal bone lesions in patients with FOP. For instance, reports have indicated reductions of 90% or greater in new heterotopic ossification. These findings have provided a strong rationale for its continued clinical development and have generated considerable hope for the FOP community. The UGaretosmab (REGN 2477) | Anti-Activin A mAb.S. Food and Drug Administration (FDA) has granted Orphan Drug status to garetosmab for FOP, acknowledging its potential to treat rare diseases and offering incentives for its developmentGaretosmab (REGN 2477) is a fully human IgG4 monoclonal antibody that specifically inhibits activin A. Garetosmab can be used for fibrodysplasia ossificans ....
Beyond its primary application in FOP, research has also explored garetosmab's potential in other conditions. Its ability to modulate activin A has led to investigations into its possible anti-cancer activity and its role in addressing muscle wasting disorders, such as Duchenne muscular dystrophy (DMD)What clinical trials have been conducted for Garetosmab?. While these areas are still under early investigation, they highlight the broader therapeutic potential of targeting the activin A pathway.Garetosmab (REGN 2477) is a fully human IgG4 monoclonal antibody that specifically inhibits activin A. Garetosmab can be used for fibrodysplasia ossificans ...
It is important to clarify garetosmab's classification. While sometimes referred to in the context of peptides due to the biological nature of activin A, garetosmab itself is a fully human IgG4 monoclonal antibody. Monoclonal antibodies are proteins produced by specialized immune cells that are designed to target specific antigens. In garetosmab's case, the target antigen is human activin A. This distinction is crucial, as antibodies and peptides are different classes of therapeutic molecules with distinct structures and mechanisms of action.Garetosmab (REGN 2477) is a fully human IgG4 monoclonal antibody that specifically inhibits activin A. Garetosmab can be used for fibrodysplasia ossificans ... Garetosmab's structure as an IgG4 antibody allows it to circulate in the bloodstream and bind to activin A with high specificity.
As an investigational drug, garetosmab is not yet widely available for general use. Its availability is primarily through participation in clinical trials. The progress of ongoing trials, such as the OPTIMA trial, will determine its future regulatory approval and eventual market availability.Garetosmabis a fully human, experimental monoclonal antibody against activin-A. It has been tried in patients with fibrodysplasia ossificans progressiva. Researchers and patients keenly await further data and potential approvals that could make garetosmab a transformative treatment option for individuals living with FOP. The development of biosimilar versions is also a possibility in the future, which could potentially increase accessibilityGaretosmab in fibrodysplasia ossificans progressiva.
In conclusion, garetosmab (REGN 2477) represents a significant stride in the therapeutic landscape for fibrodysplasia ossificans progressivaGaretosmab has potential anti-cancer activityand can be used to study ossifying fibrous dysplasia (FOP) and cancer. Supplier Catalog Number. T77019. Shipping .... As a targeted monoclonal antibody that inhibits activin A, it holds the promise of mitigating the debilitating effects of abnormal bone formation in FOP patients. Ongoing research and clinical trials are vital in confirming its safety and efficacy, paving the way for potential future therapeutic useThis study is researching an experimental drug calledgaretosmab. The study is focused on adult patients with fibrodysplasia ossificans progressiva (FOP)..
Join the newsletter to receive news, updates, new products and freebies in your inbox.